• ELRIG Drug Discovery 2021, ACC Liverpool, UK, 19–20 October• Face-to-face event aims to re-connect, re-invent, and re-imagine drug discovery• SLAS’s Innovation AveNEW promotes start-ups by awarding free-of-charge exhibition space and access to a network of potential business partners
20 August, 2021
Wallops Flight Facility, VA. August 10, 2021 - An 18-year-old high school graduate has developed an elegant new way to gauge the liver health of astronauts—and it could someday help solve an enduring medical mystery in space.
18 August, 2021
Manchester, UK, August 11, 2021: Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments. The company has a pipeline of promising drug development programmes, with the most advanced two being for cognitive impairment in schizophrenia and post-operative cognitive dysfunction (“POCD”).
16 August, 2021
(Oslo, August 5, 2021) Molecular diagnostics specialist, Genetic Analysis AS (GA) today announced the first publication from the comprehensive HumGut microbiome database has appeared in the leading scientific journal Microbiome. HumGut comprises a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut. Unique to HumGut is that the genome collection has been filtered towards nearly 6000 metagenomes from healthy humans, classifying on average 95% of all metagenome reads and making it superior to all other genome collections. This work is funded by the Norwegian University of Life Sciences (NMBU) and GA with support from the Research Council of Norway through an Industrial PhD program.
05 August, 2021